Articles tagged with "etanercept"

Etanercept Biosimilars Promising in Clinical Studies

Michele B. Kaufman, PharmD, BCGP | December 2, 2015

In multiple clinical studies, investigational biosimilars for etanercept were shown to be safe and effective for treating rheumatoid arthritis and moderate to severe plaque psoriasis…

Tofacitinib on Hold for Psoriasis, Plus Anti-TNFs Top FDA List for Adverse Events

Michele B. Kaufman, PharmD, BCGP | October 28, 2015

The FDA is asking for more safety analysis before approving tofacitinib to treat psoriasis. Also, adalimumab and etanercept received the greatest number of adverse and serious adverse events reported to the FDA in 2014…

Novartis Biosimilar Takes Aim at Amgen’s Enbrel

Michael Shields & Ben Hirschler | October 2, 2015

ZURICH (Reuters)—The U.S. Food and Drug Administration has accepted Novartis unit Sandoz’s regulatory submission for approval of a biosimilar copy of Amgen’s blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said on Friday. Enbrel, or etanercept as the drug is known generically, is a big prize since it was the world’s fifth-biggest selling medicine in 2014…

Methotrexate Halt Feasible in Some Etanercept RA Responders

David Douglas | September 21, 2015

NEW YORK (Reuters Health)—Certain rheumatoid arthritis (RA) patients doing well on etanercept and methotrexate may be able to quit the latter agent if they have tolerability problems, according to an open-label Canadian study. In a Sept. 11 online paper in Rheumatology, Dr. Boulos Haraoui, of the University of Montreal, and colleagues noted that although combination…

Biosimilar Drug Updates Reported from EULAR

Michele B. Kaufman, PharmD, BCGP | July 8, 2015

At the 2015 meeting of the European League Against Rheumatism in June, multiple studies were presented comparing the use of different biosimilar and biologic drugs in treating rheumatoid arthritis…

Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis

Reuters Staff | June 12, 2015

NEW YORK (Reuters Health)—Tofacitinib is better than placebo (and noninferior to etanercept) for treating patients with moderate-to-severe chronic plaque psoriasis, according to Pfizer’s OPT Compare trial. In an earlier 12-week, phase 2b, dose-ranging trial, the oral JAK inhibitor tofacitinib proved to be more effective than placebo for treating patients with moderate-to-severe plaque psoriasis. Based on…

Case Report: Rheumatoid Arthritis and Degenerative Disk Disease

Patricia Frisch, PhD; Ronald R. Butendieck, MD; Andy Abril, MD; Peter M. McIntosh, MD; Salim M. Ghazi, MD; Elliot L. Dimberg, MD; Lynn F. Feldman, DO; David G. Lucas, MD; and Andrea Styron, MSR-PT | March 1, 2015

Combination therapy includes abatacept for patient with erosive, chronic RA, underlying osteoarthritis and degenerative disk disease

Treat JIA Without Slowing Growth

By Sue Pondrom | January 4, 2011

Etanercept does not impede normal height and weight development in these patients